DNTH
Dianthus Therapeutics, Inc.·Healthcare
86.67
0.173%(−0.15)
Close PriceLast Updated: — ET
52W L: $16.6452W H: $96.50
Dianthus Therapeutics, Inc.·Healthcare
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026.
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
